Form: 8-K

Current report filing

May 25, 2018



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549 
 
FORM 8-K 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 25, 2018 

NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter) 
 
Nevada
 
001-35756
 
74-2897368
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
12701 Commonwealth Drive, Suite 9, Fort Myers, Florida
 
33913
(Address of principal executive offices)
 
(Zip Code)
(239) 768-0600
(Registrant’s telephone number, including area code) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐





Item 8.01
Other Matters.
NeoGenomics, Inc. (the “Company”) implemented ASU 2014-09, Revenue from Contracts with Customers (“ASC 606”), on January 1, 2018 using a full retrospective method of adoption. We have provided supplemental information and metrics to reflect the adoption of this standard in the schedules attached thereto as Exhibit 99.1.

Item 9.01.
Financial Statements and Exhibits.
 
(a)
Not applicable
(b)
Not applicable
(c)
Not applicable
(d)
Exhibits

99.1 Supplementary Information of NeoGenomics, Inc. dated May 25, 2018.

Exhibit Index

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
NEOGENOMICS, INC.
 
 
By:
/s/ Sharon A. Virag
 
Sharon A. Virag
 
Chief Financial Officer
 
May 25, 2018